134 related articles for article (PubMed ID: 15153937)
1. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
3. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
4. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
[TBL] [Abstract][Full Text] [Related]
6. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
7. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
8. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.
Miller J; Eisele G; Tabatabai G; Aulwurm S; von Kürthy G; Stitz L; Roth P; Weller M
J Neurosurg; 2010 Aug; 113(2):280-5. PubMed ID: 19961309
[TBL] [Abstract][Full Text] [Related]
11. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
14. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
[TBL] [Abstract][Full Text] [Related]
15. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
16. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.
Chahlavi A; Rayman P; Richmond AL; Biswas K; Zhang R; Vogelbaum M; Tannenbaum C; Barnett G; Finke JH
Cancer Res; 2005 Jun; 65(12):5428-38. PubMed ID: 15958592
[TBL] [Abstract][Full Text] [Related]
17. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
19. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
Giovarelli M; Santoni A; Forni G
J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
